Apr 2 |
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
|
Apr 2 |
CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
|
Apr 1 |
CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M
|
Apr 1 |
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
|
Mar 5 |
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
|
Feb 21 |
CervoMed to Participate in the BIO CEO and Investor Conference
|
Feb 20 |
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
|
Feb 12 |
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
|
Feb 5 |
CervoMed to Participate in the Emerging Growth Conference 67
|
Jan 5 |
CervoMed to Participate in the Emerging Growth Conference 66
|